ACR Convergence 2024 will be held November 14–19 at the Walter E. Washington Convention Center in Washington, D.C.

   We will present our latest diagnostic progress on SLE by IFI44L methylation assay at ACR conference. IFI44L low-methylation shows high sensitivity and specificity in the diagnosis of SLE. This is benefit for patients who could be clarified accurately in SLE or other rheumatologic disease. 

Early or preclinical SLE patients has atypical symptoms. In these periods, IFI44L present highly sensitive or specificity than commonly immune-markers. Early diagnostics and medical treatment for SLE are beneficial for patient's condition.

Additionally, IFI44L demonstrates the high predictability for recurrence prediction and medical treatment evaluation.

 And we holp meet you in ACR or you can contact us by email.